Search Results
Safety and efficacy of once-weekly carfilzomib dosing in frail patients: Phase 3 ARROW
ARROW: carfilzomib dosing in frail R/R multiple myeloma patients
A.R.R.O.W. study: carfilzomib dosing in frail MM patients
ARROW: once vs. twice weekly carfilzomib for MM
Weekly carfilzomib and dexamethasone plus/minus cyclophosphamide for RRMM patients
Weekly Carfilzomib Dosing Superior to Twice-Weekly Dosing
The combined analysis of carfilzomib trials
Carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma
Phase III ASPIRE study of carfilzomib, lenalidomide and dexamethasone in relapsed myeloma
KRd vs KTd followed by carfilzomib maintenance in newly diagnosed MM
Results of the ENDEAVOR trial comparing carfilzomib and bortezomib in multiple myeloma
Weekly 20/56 mg/m² carfilzomib, lenalidomide and dexamethasone until progression in early relaps...
